Yong-Chieh Chang
Overview
Explore the profile of Yong-Chieh Chang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feng W, Chang Y, Lin Y, Chen H, Chen C, Lin T, et al.
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259380
P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it could lower the risk of...
2.
Feng W, Chang Y, Lin Y, Chen H, Chang H, Chu C
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35562942
Increasing evidence has shown P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) with stent implantation in the modern era. However, patients with diabetes...
3.
Tsai Y, Chen H, Lee T, Chang H, Wu K, Chuang C, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008346
Patients with malignant pleural mesothelioma (MPM) have very poor prognoses, and pemetrexed plus platinum is the standard first-line therapy. However, the second-line therapy for relapsed MPM remains controversial. A comprehensive...
4.
Wu K, Chen H, Tsai Y, Lee T, Chang H, Tsai Y, et al.
J Clin Med
. 2021 Oct;
10(19).
PMID: 34640394
Various anaplastic lymphoma kinase inhibitors (ALKIs) have been approved for first-line use in treating anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). To date, no head-to-head comparison of these...
5.
Chen H, Chang H, Wu H, Lin Y, Chang Y, Chang Y, et al.
Regul Toxicol Pharmacol
. 2021 Jun;
124:104970.
PMID: 34087384
Background: Statin is biologically plausible in cataract development, but inconclusive associations between statin and cataract are presented in human studies. Given most early onset cataract (EOC) occurs in regions with...
6.
Chuang C, Chen H, Chang H, Tsai Y, Wu K, Chen I, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33921762
Several anaplastic lymphoma kinase inhibitors (ALKIs) have demonstrated excellent efficacy on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and also better adverse effect (AE) profiles compared to...
7.
Wu C, Wei P, Shen Y, Chang H, Tsai Y, Pan H, et al.
Antibiotics (Basel)
. 2019 Sep;
8(3).
PMID: 31480424
Gemifloxacin is a common oral antibiotic for lower respiratory tract infection worldwide. We noticed an uncommon delayed onset skin rash in patients who received Gemifloxacin. Therefore, we retrospectively reviewed all...
8.
Chen H, Chen T, Chang H, Juan Y, Huang W, Pan H, et al.
World J Urol
. 2018 Mar;
36(8):1285-1297.
PMID: 29556972
Purpose: Mirabegron, a β3-adrenoceptor agonist, was approved for overactive bladder (OAB), but worsened hypertension was a potential risk based on its mechanism of action. Besides, head to head comparisons were...